Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

New AI-enabled heart failure implant shows early potential
The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.
Heart failure biomarker identifies long-term risk in T-TEER patients
NT-proBNP measurements are often used to diagnose and manage heart failure. According to a new study of more than 2,000 patients, they can also provide value to cardiologists performing T-TEER.
Did you make the list? CMS targets cardiologists for new heart failure payment model
More than 2,000 cardiologists are required to participate in the new payment model. According to CMS, the long-term goal is to track and reduce the high healthcare costs associated with treating heart failure.
FDA confirms more recalls for Johnson & Johnson heart pumps due to malfunction risk
The issue, first announced to the public in February, has been linked to 22 serious injuries. Customers are urged to review the updated instructions for use to avoid any potential complications.
FDA approves next-generation CardioMEMS reader for heart failure monitoring
The updated reader is 60% smaller and offers built-in WiFi connectivity. It works with an implantable sensor to monitor a patient's PA pressure.

The Relief System from Relief Cardiovascular Inc. is a first of its kind device. It incorporates a valve and sensor implant that uses AI to intelligently modulate venous pressure using hemodynamic data. The system actively adjusts flow in the inferior vena cava (IVC), which lowers venous pressure to drive durable decongestion in heart failure.

New AI-enabled heart failure implant shows early potential

The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.

Heart failure biomarker identifies long-term risk in T-TEER patients

NT-proBNP measurements are often used to diagnose and manage heart failure. According to a new study of more than 2,000 patients, they can also provide value to cardiologists performing T-TEER.

cardiologist salary and compensation data

Did you make the list? CMS targets cardiologists for new heart failure payment model

More than 2,000 cardiologists are required to participate in the new payment model. According to CMS, the long-term goal is to track and reduce the high healthcare costs associated with treating heart failure.

FDA recall medical device recall product recall

FDA confirms more recalls for Johnson & Johnson heart pumps due to malfunction risk

The issue, first announced to the public in February, has been linked to 22 serious injuries. Customers are urged to review the updated instructions for use to avoid any potential complications.

Abbott has secured U.S. Food and Drug Administration (FDA) approval for its CardioMEMS HERO device, a next-generation pulmonary artery (PA) pressure reader for heart failure patients.

FDA approves next-generation CardioMEMS reader for heart failure monitoring

The updated reader is 60% smaller and offers built-in WiFi connectivity. It works with an implantable sensor to monitor a patient's PA pressure.

warning safety alert recall healthcare issue

FDA shares new warning about Johnson & Johnson heart pumps after 4 injuries

This represents the latest in a series of safety concerns associated with the Impella platform. The FDA said it is still reviewing the matter and will keep the public informed as new details become available.

Women of all ages face rising risks of heart disease and stroke—but cardiologists see a path forward

Cardiovascular disease is already the No. 1 killer among women—and new projections from the American Heart Association suggest things are going to get much worse. There are certain things that clinicians and patients can do, however, to help reverse this trend and save countless lives.

Heart failure company BioVentrix files for IPO

The company, known for its advanced heart failure technologies, hopes to be traded on the Nasdaq under the symbol BVXX.